FdaApplication
BLA 125714
Identifiers
- fda_app_no: BLA125714
Properties
| Property | Value |
|---|---|
| applicant_name | Juno Therapeutics, Inc. a Bristol Myer-Squibb Company |
| application_type | BLA |
| approval_date | 2021-02-05 |
Revenue by product
BREYANZI
| Period | Revenue |
|---|---|
| Q2 2026 | $484.0M |
| Q1 2026 | $411.0M |
| Q4 2025 | $392.0M |
| Q3 2025 | $359.0M |
| Q2 2025 | $344.0M |
| Q1 2025 | $263.0M |
| Q4 2024 | $263.0M |
| Q3 2024 | $224.0M |
| Q2 2024 | $153.0M |
| Q1 2024 | $107.0M |
| Q4 2023 | $101.0M |
| Q3 2023 | $92.0M |
| Q2 2023 | $100.0M |
| Q1 2023 | $71.0M |
| Q4 2022 | $55.0M |
| Q3 2022 | $44.0M |
| Q2 2022 | $39.0M |
| Q1 2022 | $44.0M |
| Q4 2021 | $40.0M |
| Q3 2021 | $30.0M |
| Q2 2021 | $17.0M |
| Q1 2021 | $0.0M |
| Q4 2020 | $0.0M |
| Q3 2020 | $0.0M |
| Q2 2020 | $0.0M |
Revenue as this company reported it for this product. A combination product's amount is stated once, for the product, and never divided across its ingredients. A fourth quarter is the reported full year less nine months, since no filing states one.
Products (1)
| Product | Active ingredient | Strength | Dosage form |
|---|---|---|---|
| BREYANZI | — | 4.6ML/VIAL | Injection |
1 product